Here are 1-3 brief analogies for Callan JMB (CJMB):

1. The 'Tesla of cold chain logistics,' offering cutting-edge, environmentally-friendly solutions for shipping sensitive biologicals.

2. Imagine FedEx or UPS, but exclusively for critical, temperature-sensitive medical and biological materials, with advanced tracking and data analysis for every shipment.

• Thermal Management Logistics Solutions: Comprehensive, vertically integrated services providing end-to-end cold chain logistics for temperature-sensitive products within the life sciences industry.
• Sentry System: A sophisticated cloud-based logistics operating platform that integrates GPS and precise temperature diagnostics to manage, track, and archive crucial information for every shipment.
• Ship2Q® Process: An ultraviolet disinfection and qualification service ensuring the fitness, thermal reliability, and cleanliness of reusable shipper systems to cGMP and cGDP compliance standards.
• Greenbox Shipper: Proprietary reusable thermal packaging designed for cryogenic or frozen shipping, offering a cost-neutral and environmentally responsible alternative to traditional methods.

Callan JMB (CJMB) primarily sells its advanced thermal management logistics solutions to other companies and organizations, rather than to individuals. The provided company description does not list specific customer company names, but it clearly identifies the industries and types of entities that utilize its services. Its major customers can be categorized as follows:

• Life Sciences Industry: This broad category encompasses a range of entities that develop, produce, research, or transport highly sensitive biological materials. This includes biopharmaceutical companies, biotechnology firms, research institutions, and organizations specializing in areas such as personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, bio-pharmaceuticals, and other commodities requiring cryogenic or frozen temperatures (e.g., semen, eggs, embryos, cord blood, organs, infectious substances).

• Healthcare Industry: Customers in this sector include hospitals, clinics, laboratories, organ transplant networks, and other healthcare providers that require reliable and compliant cold chain logistics for critical medical materials like vaccines, organs, and diagnostic samples, ensuring their efficacy and safety for patients.

• Emergency Response Sector: This refers to organizations involved in urgent medical transport, disaster relief, or other time-sensitive situations where maintaining the integrity of temperature-sensitive goods is paramount. Callan JMB's solutions empower these industries to ensure goods remain within specified parameters throughout transit.

Wayne Williams, Chief Executive Officer, Chairman & Founder

Mr. Williams is the founder of Callan JMB Inc. He also serves as the Executive Director of Warehouse Asset Management (WAM). Previously, he was the Director of Logistics for Logistics Health Inc. (LHI), where he was responsible for the management and oversight of LHI's Supply Support Technology Group and was the primary inventor for LHI's Environmental Witness System. Mr. Williams is recognized as a leading expert in Cold Chain Management and previously served as the Associate Director of Logistics for the Strategic National Stockpile (SNS) from its inception.

Christopher Shields, Interim Chief Financial Officer and Senior Vice President of Emergency Preparedness & Response/Government Affairs

Mr. Shields was appointed Interim CFO on December 1, 2025. He joined Callan JMB in April 2025 as Senior Vice President of Emergency Preparedness & Response/Government Affairs. Prior to this, he served for over 14 years as Assistant Commissioner at the Chicago Department of Public Health, where he oversaw operations and logistics for the city's Emergency Preparedness and Bioterrorism program, including managing the Tier 1 Medical Pharmacy and advanced vaccine inventory systems.

Eric L. Kash, Executive Vice President & Director

Mr. Kash has extensive experience in the United States securities markets, spanning Retail and Institutional Equity Sales to Investment Banking. He has held positions as a public company CEO and CFO, possessing both an MBA and CPA. He has also focused on assisting private companies in their efforts to go public. Before joining Callan JMB, since 2015, Mr. Kash operated Alpha Kash, LLC, a business consultancy service where he provided assistance in business development, corporate strategy, and capital formation to companies in various industries, including technology, consumer goods, medical devices, and e-prescription. Between January 2008 and March 2013, he served as the CEO/CFO of a prior company.

Scott Bullard, Chief Operating Officer

Mr. Bullard works directly with both Warehouse Asset Management (WAM) and Callan JMB. His experience includes collaborating with Merck in 1994 on his first major vaccine project.

William McBride, Chief Information Officer

Mr. McBride previously implemented a GMP quality assurance system at one of the nation's largest biological specimen repositories, where he managed over 12 million samples, more than 600 pieces of refrigeration equipment, over 800 recording instruments, and 6 separate facilities. He also served as the Manager of Compliance and Program Evaluation at Logistics Health, Inc.

The key risks to Callan JMB's business include significant financial distress, the critical need for regulatory compliance and associated liability in the life sciences cold chain, and intense competitive pressures coupled with the risk of technological obsolescence or operational failure of its proprietary systems.

1. Financial Distress and Poor Profitability: Callan JMB exhibits significant financial challenges, including an Altman Z-Score indicating distress, negative operating and net margins, and poor earnings quality. The company has reported no revenue growth over the past three years, substantial operational inefficiencies, and significant losses, with a struggling pretax profit margin and negative operating cash flow.

2. Regulatory Compliance and High-Stakes Liability: Operating in the life sciences cold chain, Callan JMB faces stringent regulations such as Good Manufacturing Practices (cGMP) and Good Distribution Practices (cGDP). Failure to adhere to these standards when handling sensitive materials like personalized medicine, cell therapies, vaccines, and organs can lead to severe penalties, product recalls, significant financial losses, damage to reputation, and even endanger patient safety. The industry is highly susceptible to temperature excursions and other disruptions, with the pharmaceutical sector alone losing billions annually due to cold chain failures.

3. Competitive Pressure and Risk of Technological Obsolescence/Operational Failure: Callan JMB operates in a competitive and evolving market, positioning its solutions as disruptive alternatives to older technologies. This environment implies a continuous threat of new, more advanced, or cost-effective solutions emerging from competitors, potentially rendering Callan JMB's offerings less competitive. Furthermore, the company's business model relies heavily on its proprietary technologies, including the Sentry cloud-based logistics platform, the Ship2Q® disinfection process, and reusable Greenbox shippers. Any operational failures, cybersecurity breaches, or inability to consistently maintain the efficacy and integrity of these complex systems could severely impact service delivery, undermine client trust, and jeopardize its economic model.

Callan JMB (CJMB) operates within several significant addressable markets related to life sciences logistics and software.

The primary services of Callan JMB, which encompass thermal management logistics solutions for the life sciences industry, including cryogenic and frozen shipping for products like personalized medicine, cell therapies, vaccines, organs, and biopharmaceuticals, fall within the:

• Global Biopharmaceutical Cold Chain Logistics Market: This market was valued at approximately USD 18.23 billion in 2024 and is projected to grow to USD 51.58 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 10.98% from 2025 to 2034. North America held the largest revenue share in this market in 2024.
• A specialized segment, the Global Cryo-Shipping Logistics for Cell Therapies Market, reached USD 1.34 billion in 2024 and is expected to grow at a robust CAGR of 17.2% to approximately USD 5.08 billion by 2033. North America currently dominates this specific market. The deep-frozen/ultra-low temperature segment (below -20°C) of the broader cold chain logistics market, which is highly relevant to Callan JMB's offerings, is projected to grow at an 8.22% CAGR through 2031. Callan JMB is also making a strategic shift towards cold-chain infrastructure to support the $100 billion GLP-1 pharmaceutical market.

Callan JMB's sophisticated cloud-based logistics operating platform, branded as the "Sentry" system, addresses a part of the:

• Global Life Science Software Market: This market was valued at USD 16.11 billion in 2024 and is projected to expand to USD 36.25 billion by 2032, growing at a CAGR of approximately 10.8% during 2025–2032. North America holds the largest share of this market.

While Callan JMB also offers a Ship2Q® ultraviolet disinfection process, a specific addressable market size for this unique service component was not readily available as it typically integrates with their broader logistics solutions.

Callan JMB (CJMB) anticipates several key drivers for its future revenue growth over the next two to three years, primarily by expanding its specialized logistics services and leveraging strategic partnerships.

Here are the expected drivers of future revenue growth:

• Expansion into New Vertical Markets: Callan JMB is actively pursuing growth opportunities by expanding its thermal management logistics solutions into specific new markets. These include glucagon-like peptide receptor-1 (GLP-1) pharmaceutical transportation, compounding pharmacy logistics, and premium food packaging services.
• Strategic Partnership with Attune Biotech for Therapeutic Deployment: A significant driver is the strategic teaming agreement with Attune Biotech. Under this agreement, Callan JMB provides manufacturing oversight, federal deployment, and commercialization support for Attune's multi-asset therapeutic pipeline, including an investigational drug for Long COVID (lodonal™). This partnership is projected to contribute approximately $25 million to $45 million in revenue for Callan JMB over the next five years.
• Leveraging Proprietary Technology and Reusable Packaging Solutions: The company plans to expand its business by utilizing its advanced cloud-based Sentry logistics operating platform, which offers GPS tracking and precise temperature diagnostics, and its proprietary Greenbox reusable thermal shippers. These solutions are designed to ensure the integrity, safety, and quality of temperature-sensitive goods, providing comprehensive and economical alternatives in logistics, thereby attracting new clients and deepening existing relationships across various industries.
• Continued Growth in Emergency Preparedness and Response: Callan JMB's established expertise in emergency preparedness and response remains a core area of focus. This legacy business, which involves protecting critical medical materials and vaccines, is expected to continue contributing to revenue growth, particularly given its relevance in current global events.

Share Issuance

• Callan JMB Inc. completed its Initial Public Offering (IPO) in February 2025, pricing 1,280,000 shares of common stock at $4.00 per share, resulting in approximately $5.12 million in gross proceeds.
• Following the IPO, underwriters partially exercised their over-allotment option, leading to the issuance of an additional 163,569 shares at $4.00 each, generating an extra $654,276 in gross proceeds.
• The company has an active common stock purchase agreement with Hexstone Capital, LLC, which was amended in March 2026 to extend its maturity date to April 1, 2027, serving as an ongoing source of equity financing.

Inbound Investments

• Callan JMB Inc. raised approximately $4.73 million in net proceeds from its initial public offering in February 2025.
• The net proceeds from the IPO are primarily designated for sales support, marketing efforts, customer expansion, and general corporate purposes, including working capital.
• The equity purchase agreement with Hexstone Capital, LLC, which allows for the sale of common stock over time, represents a continuing capital source for the company.

Capital Expenditures

• In January 2026, Callan JMB initiated the phase-one retrofitting of its Texas facility to accommodate high-capacity pharmaceutical-grade refrigeration units, signaling a strategic investment in cold-chain infrastructure.
• The company is deploying a new line of proprietary, eco-friendly thermal shippers equipped with real-time IoT sensors, indicating capital investment in advanced packaging technology.